“SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design.”, Am J Ophthalmol, vol. 148, no. 5, pp. 725-732.e7, 2009.
, “SCORE Study Report 7: Incidence of Intravitreal Silicone Oil Droplets Associated with Staked-on vs. Luer Cone Syringe Design”, Am J Ophthalmol, vol. 148, pp. 725-732 e7, 2009.
, “SCORE Study Report 5: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid f”, Archives of Ophthalmology, vol. 127, pp. 1101-1114, 2009.
, “SCORE Study Report 3: Study Design and Baseline Characteristics”, Ophthalmology, vol. 116, pp. 1770-1777 e1, 2009.
, “SCORE Study report 3: study design and baseline characteristics.”, Ophthalmology, vol. 116, no. 9, pp. 1770-1777.e1, 2009.
, “SCORE Study Report 2: Interobserver Agreement Between Investigator and Reading Center Classification of Retinal Vein Occlusion Type”, Ophthalmology, vol. 116, pp. 756-761, 2009.
, “SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.”, Ophthalmology, vol. 116, no. 4, pp. 756-61, 2009.
, “Score Study Report 12: Development of venous collaterals in the Score Study.”, Retina, vol. 33, no. 2, pp. 287-95, 2013.
, “SCORE Study Report 12: Development of Venous Collaterals in the SCORE Study”, Retina, vol. 33, pp. 287-295, 2013.
, “SCORE Study Report #11: Incidences of Neovascular Events in Eyes with Retinal Vein Occlusion”, Ophthalmology, vol. 118, pp. 1364-1372, 2011.
, “SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.”, Ophthalmology, vol. 118, no. 7, pp. 1364-72, 2011.
, “Score Study Report 1: Baseline Associations Between Central Retinal Thickness and Visual Acuity in Patients with Retinal Vein Occlusion”, Ophthalmology, vol. 116, pp. 504-512, 2009.
, “SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion.”, Ophthalmology, vol. 116, no. 3, pp. 504-12, 2009.
, “School outcomes in children registered in the studies for pediatric liver transplant (SPLIT) consortium.”, Liver Transpl, vol. 16, no. 9, pp. 1041-8, 2010.
, “School Outcomes in Children Registered in The Studies for Pediatric Liver Transplant (SPLIT) Consortium”, Liver Transpl, vol. 16, pp. 1041-1048, 2010.
, “A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.”, Vaccine, vol. 26, no. 50, pp. 6338-43, 2008.
, “A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial”, Vaccine, vol. 26, pp. 6338-6343, 2008.
, “Sample-path insensitivity of symmetric queues in discrete-time.”, Nonlinear Analysis: Theory, Methods, and Applications, vol. 30, pp. 1099-110, 1997.
, “Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.”, AIDS Res Hum Retroviruses, vol. 13, no. 14, pp. 1163-77, 1997.
, “Safety profile of Phase I and II preventive HIV tTpe 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group,”, AIDS Res Hum Retroviruses, vol. 13, pp. 1163-77, 1997.
, “Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: Rationale and methods of a phase II randomized trial.”, Contemp Clin Trials Commun, vol. 30, p. 101025, 2022.
, “Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group.”, Transplantation, vol. 67, no. 4, pp. 544-7, 1999.
, “Safety of kidney biopsy in pediatric transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)”, transplantation, vol. 67, pp. 544-47, 1999.
, , “Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.”, Antimicrob Agents Chemother, vol. 66, no. 12, p. e0093522, 2022.
,